Glucosamine for Osteoarthritis
The evidence for glucosamine in osteoarthritis is genuinely conflicting and, at best, weak: the largest independent trials of the hydrochloride form found it no better than placebo, while a more favorable signal exists only for the European prescription crystalline sulfate, and even there the benefit is small. Most major regulators and U.S. guidelines recommend against it.
Why this grade7-layer evidence engine
This claim is graded weak and disputed because high-quality reviews flatly contradict each other, and the split tracks the chemical form. The NIH-funded GAIT program, the largest and most rigorous trials, used glucosamine hydrochloride and found no benefit over placebo for knee pain at 24 weeks (PMID 16495392) or over two years (PMID 20525840), and no slowing of joint-space narrowing (PMID 18821708). Because these government-funded, well-powered trials were consistently negative, the hydrochloride form sold in many products has little support.
A more positive picture exists only for the European prescription crystalline glucosamine sulfate. An umbrella review (PMID 33488785) linked this specific form to reduced pain and slowed joint narrowing, but rated the evidence merely suggestive, acknowledged industry-affiliated authorship, and stressed the findings do not extend to generic sulfate or hydrochloride. Reviews also show pain relief appears on the subjective VAS scale yet largely disappears on the more robust WOMAC scale (PMID 37489348, PMID 29947998). Some combination products perform better in pooled analyses (PMID 35024906, PMID 39685902), but these are not the main endpoints.
Authoritative bodies lean negative. EFSA concluded a cause-and-effect relationship has not been established; the UK NHS no longer prescribes it citing no strong evidence; and the American College of Rheumatology strongly recommends against glucosamine for knee, hip, or hand osteoarthritis. The Cleveland Clinic and NIH note only modest, mixed results. Exercise, weight loss, and NSAIDs are the guideline-backed first-line options; cautions include shellfish allergy and a warfarin interaction that can raise bleeding risk.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.483
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 內部嚴重矛盾 (2 positive vs 2 negative，各 ≥2)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status